Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors.
BRCA
DNA repair deficiency
biomarker
cancer
immune checkpoint inhibitors
immunotherapy
microsatellite instability
Journal
Immunotherapy
ISSN: 1750-7448
Titre abrégé: Immunotherapy
Pays: England
ID NLM: 101485158
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
pubmed:
9
9
2021
medline:
2
2
2022
entrez:
8
9
2021
Statut:
ppublish
Résumé
Faithful DNA replication is necessary to maintain genome stability and implicates a complex network with several pathways depending on DNA damage type: homologous repair, nonhomologous end joining, base excision repair, nucleotide excision repair and mismatch repair. Alteration in components of DNA repair machinery led to DNA damage accumulation and potentially carcinogenesis. Preclinical data suggest sensitivity to immune checkpoint inhibitors in tumors with DNA repair deficiency. Here, we review clinical studies that explored the use of immune checkpoint inhibitor in patient harboring tumor with DNA repair deficiency.
Identifiants
pubmed: 34494466
doi: 10.2217/imt-2021-0024
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM